The designed proteins block hemoglobin from binding ChuA, an outer membrane bacterial protein, helping to inhibit E. coli's growth.

Pharmaceutical manufacturers are under immense pressure to streamline their processes, reduce waste, and improve output.

GREmLN leverages a graph-based architecture to represent gene-gene interactions to predict cell behavior for therapeutic ...

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...